HC Wainwright Reaffirms Buy Rating for Kura Oncology (NASDAQ:KURA)

HC Wainwright restated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note released on Wednesday,Benzinga reports. The brokerage currently has a $32.00 price target on the stock.

Several other equities analysts have also issued reports on KURA. UBS Group started coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target for the company. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Monday, September 9th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Stock Down 0.5 %

Shares of NASDAQ:KURA opened at $17.68 on Wednesday. The firm has a market capitalization of $1.35 billion, a P/E ratio of -7.49 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. The stock has a 50 day moving average price of $18.78 and a 200-day moving average price of $20.00. Kura Oncology has a 52-week low of $8.17 and a 52-week high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter in the prior year, the firm posted ($0.53) EPS. The company’s revenue was up .0% on a year-over-year basis. As a group, equities research analysts anticipate that Kura Oncology will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Kura Oncology by 12.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,970 shares of the company’s stock worth $874,000 after purchasing an additional 4,659 shares during the period. SG Americas Securities LLC bought a new stake in shares of Kura Oncology in the first quarter worth about $110,000. Susquehanna Fundamental Investments LLC bought a new position in Kura Oncology during the first quarter valued at approximately $507,000. ProShare Advisors LLC grew its holdings in Kura Oncology by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after buying an additional 1,588 shares in the last quarter. Finally, Entropy Technologies LP bought a new stake in Kura Oncology in the 1st quarter worth approximately $218,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.